Literature DB >> 3334954

Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up.

Y Najean1, A Deschamps, C Dresch, M T Daniel, J D Rain, J P Arrago.   

Abstract

The analysis of 288 cases of polycythemia vera (PV) with a minimal follow-up of 10 years enabled us to study the characteristics of acute leukemia as observed in 33 patients (11.4%). In 50% of the patients (16 of 33), the malignant transformation is of the refractory anemia with excess of blasts (RAEB) type. Half of these further transform to acute nonlymphocytic leukemia (ANLL). Their life expectancy is not better than patients who abruptly develop ANLL. Leukemic transformation shows a frequency peak in the eighth year after initial evaluation in PV treated with chemotherapy and in the 11th year in patients treated with radiotherapy. In 30% of the patients myelofibrosis, or the spent phase of PV, is present before the transformation to acute leukemia (AL). This complication is, however, part of the natural history of PV and is observed in 20% of PV patients at 10 years when leukemic transformation is absent. Marrow fibrosis can therefore not be considered as a preleukemic phase. It was also noted that the occurrence of myeloid metaplasia/myelofibrosis is more frequent and begins earlier in patients treated by phlebotomy alone, and who do not transform to leukemia. The clinical characteristics of these AL, including high frequency of partial marrow invasion, difficulties in cytologic classification, a peak incidence similar to that in patients treated by chemotherapy or radiotherapy for a prior malignancy, multiple chromosome abnormalities, and poor response to therapy are all highly suggestive of secondary leukemias.

Entities:  

Mesh:

Year:  1988        PMID: 3334954     DOI: 10.1002/1097-0142(19880101)61:1<89::aid-cncr2820610115>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Treatment of polycythemia vera with recombinant interferon.

Authors:  Richard T Silver
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.

Authors:  Despina Mavrogianni; Nora Viniou; Evi Michali; Evangelos Terpos; John Meletis; George Vaiopoulos; Marina Madzourani; Gerasimos Pangalis; Xenophon Yataganas; Dimitris Loukopoulos
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

4.  Immunophenotypic characterisation of acute leukaemia after polycythemia vera.

Authors:  J M Hernández; A Orfao; M González; B Cuesta; M C López-Berges; M C Cañizo; J Ciudad; J F San Miguel
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

5.  Use and risks of phosphorus-32 in the treatment of polycythaemia vera.

Authors:  Claude Parmentier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-03       Impact factor: 9.236

Review 6.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.